412961-26-3

Basic information

• Product Name: 3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID
• Synonyms: 3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID;2,3-Difluoro-benzenepropanoic acid;3-(2,3-Difluorophenyl)propanoic acid
• CAS NO: 412961-26-3
• Molecular Formula: C₉H₈F₂O₂
• Molecular Weight: 186.16
• Mol File: 412961-26-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 272.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.312±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.57±0.10(Predicted)
• CAS DataBase Reference: 3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID(412961-26-3)
• EPA Substance Registry System: 3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID(412961-26-3)

Safety Data

• Hazardous Substances Data: 412961-26-3(Hazardous Substances Data)

Usage

Description

3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID is a chemical compound with the molecular formula C9H8F2O2. It is a non-steroidal anti-inflammatory drug (NSAID) with potential analgesic and anti-inflammatory properties. It works by inhibiting the production of prostaglandins, which are involved in the inflammatory response.
Used in Pharmaceutical Industry:
3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID is used as an analgesic and anti-inflammatory agent for the treatment of pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis.
Used in Oncology Research:
3-(2,3-DIFLUOROPHENYL)PROPIONIC ACID is used as a potential chemopreventive agent in the prevention of colon cancer and in combination with other drugs for the treatment of various cancers.

Upstream product

• 236746-13-7 2,3-difluorocinnamic acid 
• 207981-48-4 2,3-difluorocinnamic acid 
• 2033-24-1 cycl-isopropylidene malonate 
• 2646-91-5 2,3-difluorobenzaldehyde 

Downstream Products

• 412961-97-8 3-(2,3-difluorophenyl)propionoyl chloride 
• 628732-11-6 4,5-difluoro-2,3-dihydro-1H-inden-1-one 
• 628732-15-0 2-(4,5-difluoro-indan-1-yl)-ethanol 

Relevant articles and documents

CHEMICAL COMPOUNDS

The use of a compound of formula (I) wherein X is (i), (ii) or (iii), formula (i),formula (ii), formula (iii) Y is O, S(O)m, NR3, CR5R6, CR5R6-CR7R8, O-CR7R

4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

NOVEL COMPOUNDS

Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis. In Formula (I) R1, R2, R3, R4, R5, R6, X and Y are as d